Full text is available at the source.
Abstract
Tirzepatide has an incremental cost-effectiveness ratio of $42,705/QALY for U.S. adults with metabolic dysfunction-associated steatohepatitis (MASH) and F2-F3 fibrosis.
- Tirzepatide provides the largest quality-adjusted life year (QALY) gain among the therapies evaluated.
- Semaglutide is also considered cost-effective, with an incremental cost-effectiveness ratio of $80,076/QALY.
- Resmetirom exceeds the willingness-to-pay threshold with an incremental cost-effectiveness ratio of $273,445/QALY.
- Drug price significantly influences cost-effectiveness outcomes in sensitivity analyses.
- Probabilistic sensitivity analysis indicates a 99.5% probability of cost-effectiveness for tirzepatide and 89.8% for semaglutide at the $100,000/QALY threshold.
Simplified